AU2019294819B2 - Substituted alkylphenols as HCN1 antagonists - Google Patents

Substituted alkylphenols as HCN1 antagonists Download PDF

Info

Publication number
AU2019294819B2
AU2019294819B2 AU2019294819A AU2019294819A AU2019294819B2 AU 2019294819 B2 AU2019294819 B2 AU 2019294819B2 AU 2019294819 A AU2019294819 A AU 2019294819A AU 2019294819 A AU2019294819 A AU 2019294819A AU 2019294819 B2 AU2019294819 B2 AU 2019294819B2
Authority
AU
Australia
Prior art keywords
alkyl
substituted
unsubstituted
compound
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019294819A
Other languages
English (en)
Other versions
AU2019294819A1 (en
Inventor
Dipti N. Barman
Peter Goldstein
Rebecca L. JOYCE
Anthony A. Sauve
Gareth R. TIBSS
Rajendra Uprety
James David WARREN Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell University
Original Assignee
Cornell University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell University filed Critical Cornell University
Publication of AU2019294819A1 publication Critical patent/AU2019294819A1/en
Application granted granted Critical
Publication of AU2019294819B2 publication Critical patent/AU2019294819B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/82—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/82—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups
    • C07C49/825—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups all hydroxy groups bound to the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/82—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups
    • C07C49/835—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups having unsaturation outside an aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/32—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by aldehydo- or ketonic radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Epoxy Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2019294819A 2018-06-27 2019-06-27 Substituted alkylphenols as HCN1 antagonists Active AU2019294819B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862690778P 2018-06-27 2018-06-27
US62/690,778 2018-06-27
US201962803109P 2019-02-08 2019-02-08
US62/803,109 2019-02-08
PCT/US2019/039493 WO2020006224A1 (en) 2018-06-27 2019-06-27 Substituted alkylphenols as hcn1 antagonists

Publications (2)

Publication Number Publication Date
AU2019294819A1 AU2019294819A1 (en) 2021-02-18
AU2019294819B2 true AU2019294819B2 (en) 2025-04-03

Family

ID=67297385

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019294819A Active AU2019294819B2 (en) 2018-06-27 2019-06-27 Substituted alkylphenols as HCN1 antagonists

Country Status (7)

Country Link
US (2) US11684590B2 (https=)
EP (1) EP3813948A1 (https=)
JP (1) JP7583438B2 (https=)
CN (1) CN113226468B (https=)
AU (1) AU2019294819B2 (https=)
CA (1) CA3145096A1 (https=)
WO (1) WO2020006224A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019294819B2 (en) * 2018-06-27 2025-04-03 Cornell University Substituted alkylphenols as HCN1 antagonists
WO2024143404A1 (ja) * 2022-12-26 2024-07-04 ダイキン工業株式会社 アルキレン鎖含有シラン化合物
CN117326999B (zh) * 2023-09-12 2025-11-18 辽宁靖帆新材料有限公司 一种二苯基[4-(苯硫基)苯基]全氟丁基磺酸锍盐的合成方法
CN117263796A (zh) * 2023-09-22 2023-12-22 安徽昊帆生物有限公司 十八烷二酸单叔丁酯的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011019747A1 (en) * 2009-08-11 2011-02-17 The Trustees Of Columbia University In The City Of New York Compositions and methods of treating chronic pain by administering propofol derivatives

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1811322A1 (de) * 1968-11-28 1970-06-25 Merck Ag E Stabilisatoren
EP0303894A3 (en) 1987-08-18 1991-03-20 American Cyanamid Company Radiation sterilizable composition and articles made therefrom
US4820755A (en) 1987-08-18 1989-04-11 American Cyanamid Company Radiation sterilizable composition and articles made therefrom
JP2754039B2 (ja) * 1988-06-24 1998-05-20 塩野義製薬株式会社 ジ―ｔｅｒｔ―ブチルヒドロキシフェニルチオ誘導体
ATE161717T1 (de) * 1989-07-14 1998-01-15 Biodor Us Holding Corp Antivirale mittel
JPH03149287A (ja) * 1989-11-06 1991-06-25 Eisai Co Ltd フェノール誘導体
US5126487A (en) 1991-03-26 1992-06-30 The Procter & Gamble Company Process for the preparation of 2-alkyl-4-acyl-6-tert-butylphenol compounds
AU5833494A (en) 1992-12-22 1994-07-19 Smithkline Beecham Plc Piperidine derivatives as calcium channel antagonists
EP0761652A1 (en) 1995-08-01 1997-03-12 Mochida Pharmaceutical Co., Ltd. Acridinium compound having a plurality of luminescent groups and binding groups, and conjugate thereof
US6218437B1 (en) 1996-09-30 2001-04-17 The Regents Of The University Of California Treatment and prevention of hepatic disorders
JPH10195258A (ja) 1997-01-08 1998-07-28 Asahi Denka Kogyo Kk 農業用フィルム組成物
JP2003231777A (ja) 2002-02-07 2003-08-19 Mitsui Chemicals Inc 農業フィルム用ポリオレフィン樹脂組成物および農業用フィルム
AU2005249410A1 (en) 2004-05-14 2005-12-15 Emisphere Technologies, Inc. Aryl ketone compounds and compositions for delivering active agents
US7511077B2 (en) * 2005-02-09 2009-03-31 Neuromed Pharmaceuticals Ltd. Diamine calcium channel blockers
WO2007054446A1 (en) 2005-11-09 2007-05-18 Ciba Holding Inc. Photolatent systems
JP5029083B2 (ja) * 2007-03-16 2012-09-19 富士ゼロックス株式会社 静電荷像現像用トナー、静電荷像現像用現像剤及び画像形成装置
JPWO2011001974A1 (ja) * 2009-07-01 2012-12-13 Jx日鉱日石金属株式会社 Ｃｕ−Ｇａターゲット及びその製造方法
CN102382037B (zh) 2010-09-03 2016-01-20 中国医学科学院药物研究所 苯丙酸类化合物及其制法和药物用途
WO2013024040A2 (en) 2011-08-12 2013-02-21 B.S.R.C. Alexander Fleming Tnf superfamily trimerization inhibitors
JP5991530B2 (ja) * 2012-11-02 2016-09-14 Dic株式会社 ビスフェノール誘導体
WO2014101237A1 (zh) 2012-12-31 2014-07-03 深圳诺普信农化股份有限公司 抗光解农药及其应用
KR20170003527A (ko) 2014-02-24 2017-01-09 유리젠 파마슈티컬스, 인코포레이티드 경구 투여용 펜토산 폴리설페이트 염의 조성물
US9752093B2 (en) * 2015-06-04 2017-09-05 Chevron Oronite Company Llc Borated polyol ester of hindered phenol antioxidant/friction modifier with enhanced performance
AU2019294819B2 (en) * 2018-06-27 2025-04-03 Cornell University Substituted alkylphenols as HCN1 antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011019747A1 (en) * 2009-08-11 2011-02-17 The Trustees Of Columbia University In The City Of New York Compositions and methods of treating chronic pain by administering propofol derivatives

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AMIN MANTEGHI ET AL: "Polyolefin elastomer grafted unsaturated hindered phenol esters: synthesis and antioxidant behavior", DESIGNED MONOMERS AND POLYMERS, 2016, 19(6): 569-576. DOI: 10.1080/15685551.2016.1187442 *
RAHMAN S.S. ET AL: "Infrared and raman spectra of single resin bead for analysis of solid-phase reactions and use in encoding combinatorial libraries", JOURNAL OF ORGANIC CHEMISTRY, 1998, 63: 6196-6199. *
YUAN-HSIAO SU ET AL: "Solution-phase parallel synthesis and screening of anti-tumor activities from fenbufen and ethacrynic acid libraries", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS. 2011, 21(5): 1320-1324. DOI: 10.1016/J.BMCL.2011.01.068. *

Also Published As

Publication number Publication date
US20210267909A1 (en) 2021-09-02
CN113226468B (zh) 2025-03-25
EP3813948A1 (en) 2021-05-05
WO2020006224A1 (en) 2020-01-02
US20240366529A1 (en) 2024-11-07
AU2019294819A1 (en) 2021-02-18
US12274679B2 (en) 2025-04-15
CN113226468A (zh) 2021-08-06
CA3145096A1 (en) 2020-01-02
US11684590B2 (en) 2023-06-27
JP7583438B2 (ja) 2024-11-14
JP2021529778A (ja) 2021-11-04

Similar Documents

Publication Publication Date Title
US12274679B2 (en) Substituted alkylphenols as HCN1 antagonists
US20240269093A1 (en) Use of metformin and analogs thereof to reduce ran protein levels in the treatment of neurological disorders
US11905285B2 (en) Inhibitors of plasma kallikrein and uses thereof
US20190192532A1 (en) Combination therapy of bromodomain inhibitors and checkpoint blockade
JP2016511744A (ja) Ｐｒｍｔ５を阻害する方法
JP2016505001A (ja) Ｐｒｍｔ５阻害剤およびその使用
US20230167081A1 (en) 5-amino-2-piperidinon-3-yl-1-oxoisoindoline derivatives for degradation of ikzf2 degraders
WO2012006104A2 (en) Compounds and methods for treating tuberculosis infection
WO2023141470A2 (en) Immunomodulatory lipids and uses thereof
WO2019195682A1 (en) Aryl hydrocarbon receptor modulators and uses thereof
JP2019505548A (ja) Ｍｙｃモジュレーターとしてのｍａｘバインダーおよびこれらの使用
EP4709372A1 (en) Small molecule inhibitors of glutaminase
WO2024249763A2 (en) Prmt5 synthetic lethal inhibitors targeting mtap deleted cancers
WO2024086705A2 (en) Bicyclic enhancers of the particulate guanylyl cyclase receptor a
AU2019318046A1 (en) Histone demethylase 5 inhibitors and uses thereof
WO2025024605A1 (en) Rev-erb antagonists
WO2024086717A2 (en) Heteroaryl enhancers of the particulate guanylyl cyclase receptor a
WO2025024550A1 (en) Rev-erb antagonists
EP4593820A2 (en) Small molecule degraders of hiv-1 tat protein
WO2020198367A1 (en) COMPOUNDS FOR USES IN PHARMACOLOGICAL INDUCTION OF HBF FOR TREATMENT OF SICKLE CELL DISEASE AND β-THALASSEMIA

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)